Sage: Promising Results in Phase 2 Study in Mild Cognitive Impairment, Alzheimer's Dementia

 

• Data to be Presented During the Emerging Science Session at the American Academy of Neurology’s 74th Annual Meeting
• The LUMINARY Study is a Phase 2, open-label study evaluating the safety, tolerability and efficacy of SAGE-718 once daily in individuals with mild cognitive impairment and mild dementia due to Alzheimer’s disease
• SAGE-718 demonstrated improvement across multiple tests of executive performance as well as improvement on key tests of learning and memory in the LUMINARY Study

https://www.biospace.com/article/releases/sage-therapeutics-announces-presentation-of-promising-results-from-the-phase-2-luminary-study-of-sage-718-in-patients-with-mild-cognitive-impairment-and-mild-dementia-due-to-alzheimer-s-disease/